Skip to main content

Humanin vs SS-31

Both Humanin and SS-31 are used for mitochondrial and longevity. Here's how their evidence, dosing, and regulatory status actually compare.

Humanin

Evidence B

Humanin (HN)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

View full Humanin profile →

SS-31

Evidence B+

Elamipretide (SS-31)

A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.

View full SS-31 profile →

Side-by-Side

AttributeHumaninSS-31
Evidence GradeBB+
FDA StatusNot FDA-approved — mitochondrial-derived peptide research compoundNot FDA-approved — Phase 3 trials for primary mitochondrial myopathy
Typical DoseResearch range: 0.5–1 mg subcutaneous (rare clinical use)Trial range: 40 mg subcutaneous daily
Clinics Indexed529
Categoriesmitochondrial, longevity, neuroprotectionmitochondrial, longevity

Key reported benefits — Humanin

  • Cytoprotection
  • Anti-amyloid effects
  • Insulin sensitization

Key reported benefits — SS-31

  • Mitochondrial cardiolipin support
  • ATP production
  • Reduced oxidative damage

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons